We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
Read MoreHide Full Article
KemPharm, Inc. was up 7.27% on Sep 28 after the company announced top-line data from its phase I study evaluating serdexmethylphenidate (SDX) for cardiovascular safety.
SDX is KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH).
KemPharm initiated the phase I study in the first quarter of 2022, evaluating SDX in comparison to Ritalin (racemic methylphenidate), a commonly prescribed CNS stimulant. In the data reported from this study, the company confirmed the relative cardiovascular effects and pharmacokinetics of serdexmethylphenidate (SDX) compared to Ritalin.
The initial data from phase I of the SDX study exhibited a potential for higher doses (80mg and 200mg) of SDX to be completely safe and well-tolerated in subjects compared to two doses of 40 mg of Ritalin. The tolerability of higher doses of SDX is expected to result in improved efficacy of the prodrug candidate, KP1077, in KemPharm’s portfolio.
The pharmacokinetic and pharmacodynamic data from the study confirmed that the doses of SDX released d-MPH as designed and in a manner that is expected to be well-suited for treating idiopathic hypersomnia (IH).
Based on the phase I SDX study data, KemPharm anticipates initiating a phase II study of KP1077 in patients with IH in the fourth quarter of 2022. Pursuant to the phase I data, KemPharm believes that the initial dosing strengths of KP1077 in the phase II study will be well tolerated among participants compared to other methylphenidate products that are used for the treatment of IH.
The company also intends to initiate a phase II study evaluating KP1077 in patients with narcolepsy in 2023.
Shares of KemPharm declined 28.8% in the year-to-date period, compared to the industry’s fall of 29.3%.
Image Source: Zacks Investment Research
KemPharm is a biopharma company focused on developing treatments for CNS disorders and rare diseases.
Apart from KP1077, the company has yet another prodrug product candidate, KP879, being evaluated for treating stimulant use disorder (“SUD”).
Acer Therapeutics’ loss per share estimates for 2022 remained steady at $2.47 in the past 30 days. The same for 2023 has remained steady at $1.07 during the same time frame.
Earnings of Acer missed estimates in two of the trailing four quarters and beat the same on the remaining two occasions. The average negative earnings surprise for ACER is 106.16%.
Aerie Therapeutics’ loss per share estimates for 2022 have remained steady at $1.82 over the past 30 days. The same for 2023 has remained steady at 96 cents over the same time frame.
Earnings of Aerie beat estimates in three of the trailing four quarters and missed the same in the remaining occasion. The average earnings surprise for AERI is 70.27%.
Soleno Therapeutics’ loss per share estimates for 2022 have remained steady at $4.05 over the past 30 days. The same for 2023 has remained steady at $2.10 in the same time frame.
Earnings of Soleno missed estimates in three of the trailing four quarters and were in line on the remaining occasion. The average earnings surprise for SLNO is 11.40%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
KemPharm, Inc. was up 7.27% on Sep 28 after the company announced top-line data from its phase I study evaluating serdexmethylphenidate (SDX) for cardiovascular safety.
SDX is KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH).
KemPharm initiated the phase I study in the first quarter of 2022, evaluating SDX in comparison to Ritalin (racemic methylphenidate), a commonly prescribed CNS stimulant. In the data reported from this study, the company confirmed the relative cardiovascular effects and pharmacokinetics of serdexmethylphenidate (SDX) compared to Ritalin.
The initial data from phase I of the SDX study exhibited a potential for higher doses (80mg and 200mg) of SDX to be completely safe and well-tolerated in subjects compared to two doses of 40 mg of Ritalin. The tolerability of higher doses of SDX is expected to result in improved efficacy of the prodrug candidate, KP1077, in KemPharm’s portfolio.
The pharmacokinetic and pharmacodynamic data from the study confirmed that the doses of SDX released d-MPH as designed and in a manner that is expected to be well-suited for treating idiopathic hypersomnia (IH).
Based on the phase I SDX study data, KemPharm anticipates initiating a phase II study of KP1077 in patients with IH in the fourth quarter of 2022. Pursuant to the phase I data, KemPharm believes that the initial dosing strengths of KP1077 in the phase II study will be well tolerated among participants compared to other methylphenidate products that are used for the treatment of IH.
The company also intends to initiate a phase II study evaluating KP1077 in patients with narcolepsy in 2023.
Shares of KemPharm declined 28.8% in the year-to-date period, compared to the industry’s fall of 29.3%.
Image Source: Zacks Investment Research
KemPharm is a biopharma company focused on developing treatments for CNS disorders and rare diseases.
Apart from KP1077, the company has yet another prodrug product candidate, KP879, being evaluated for treating stimulant use disorder (“SUD”).
KemPharm, Inc. Price
KemPharm, Inc. price | KemPharm, Inc. Quote
Zacks Rank and Stocks to Consider
KemPharm currently has a Zacks Rank #3 (Hold).
Some better-ranked stock in the same sector is Acer Therapeutics (ACER - Free Report) , Aerie Pharmaceuticals and Soleno Therapeutics (SLNO - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Acer Therapeutics’ loss per share estimates for 2022 remained steady at $2.47 in the past 30 days. The same for 2023 has remained steady at $1.07 during the same time frame.
Earnings of Acer missed estimates in two of the trailing four quarters and beat the same on the remaining two occasions. The average negative earnings surprise for ACER is 106.16%.
Aerie Therapeutics’ loss per share estimates for 2022 have remained steady at $1.82 over the past 30 days. The same for 2023 has remained steady at 96 cents over the same time frame.
Earnings of Aerie beat estimates in three of the trailing four quarters and missed the same in the remaining occasion. The average earnings surprise for AERI is 70.27%.
Soleno Therapeutics’ loss per share estimates for 2022 have remained steady at $4.05 over the past 30 days. The same for 2023 has remained steady at $2.10 in the same time frame.
Earnings of Soleno missed estimates in three of the trailing four quarters and were in line on the remaining occasion. The average earnings surprise for SLNO is 11.40%.